JPX · 4564.T
OncoTherapy Science, Inc.
¥18+¥1 (+5.88%)
OncoTherapy Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
Loading market information…
JPX · 4893.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Noile-Immune Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 60.83% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Noile-Immune Biotech Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -¥7. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Noile-Immune Biotech Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 2015 and based in Minato, Japan, this company is dedicated to exploring and advancing CAR-T cell technology for use in cancer immunotherapy treatments.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 12, 2025 | -¥6 | ¥2.14M |
|---|
| Q4 2024 | Feb 14, 2025 | -¥4+80.41% vs estimate | ¥2M-99.36% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -¥2-115.21% vs estimate | ¥3M+14.81% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥18+¥1 (+5.88%)
OncoTherapy Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.06% below the high.
¥403-¥16 (-3.82%)
J-Pharma Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.19% below the high.
¥89-¥3 (-3.26%)
Chiome Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.56% below the high.
¥800-¥1 (-0.12%)
ADR120S, Inc.’s quoted price sits in the lower half of its reported 52-week range, 10.11% below the high.
¥135-¥1 (-0.74%)
TMS Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.18% below the high.
¥40-¥1 (-2.44%)
BrightPath Biotherapeutics Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
¥132+¥2 (+1.54%)
PRISM BioLab Co.,LTD’s quoted price sits in the lower half of its reported 52-week range, 52.69% below the high.
¥200+¥2 (+1.01%)
Linical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.34% below the high.
